2017
CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA
Jameyfield E, Blondin N. CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA. Neuro-Oncology 2017, 19: vi40-vi40. PMCID: PMC5691966, DOI: 10.1093/neuonc/nox168.156.Peer-Reviewed Original ResearchMetastatic basal cell carcinomaBasal cell carcinomaCell carcinomaIntracranial invasionInitial treatmentNeurological symptomsScalp woundsVismodegib treatmentScalp basal cell carcinomasMonths of treatmentBest treatment optionYear old manLeft frontal lobeFurther medical attentionFocal cerebritisAge 78BCC patientsIncomplete resectionComplete responseScalp lesionsIntracranial complicationsTreatment optionsVasogenic edemaMohs surgeryPrevalent cancer
2016
ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI
Blondin N. ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.007.Peer-Reviewed Original ResearchSignificant radiographic improvementGliomatosis cerebriRadiographic improvementDiagnostic biopsyCerebral lobesRadiation therapyDiffuse astrocytomasTTFields therapyCombination of TTFieldsCycles of TMZYear old manYear old womanEffective treatment strategiesTumor treating fields therapyTumor Treating FieldsActive diseasePerformance statusRadiographic progressionSurvival benefitAdult astrocytomasNeurological toxicityPatient 1Patient 2Poor prognosisMalignant disease